Skye Bioscience announces glaucoma treatment receives FDA authorization for new drug application

Skye Bioscience Chairman & CEO Punit Dhillon joins Natalie Stoberman from the Proactive newsroom to share the announcement of its SBI-100 OE glaucoma treatment receiving FDA authorization for an Investigational New Drug Application.

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.

#proactiveinvestors #skyebioscience #OTCQB #SKYE #bioscience #glaucoma #fda #cannabis #cannabinoid

You might like

© 2022 The Latest StockMarket News and Interviews